MedTrace Logo

A Study of MLN0264 in Participants With Cancer of the Stomach or Gastroesophageal Junction

NCT02202759 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2017-05-15

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the efficacy, safety and tolerability of MLN0264 in patients with recurrent or metastatic guanylyl cyclase C (GCC)-positive adenocarcinoma of the stomach or gastroesophageal junction.

Conditions

  • Adenocarcinoma of the Stomach
  • Gastroesophageal Junction Expressing Guanylyl Cyclase C

Interventions

DRUG

MLN0264

MLN0264 IV infusion

Sponsors & Collaborators

  • Millennium Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Medical Director Clinical Science · Millennium Pharmaceuticals, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-04
Primary Completion
2016-01-15
Completion
2016-01-15

Countries

  • United States
  • Belgium
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02202759 on ClinicalTrials.gov